{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:38:46Z","timestamp":1792719526615,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lungcan.2026.109644","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:21:09Z","timestamp":1791933669000},"page":"109644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0693-3747","authenticated-orcid":false,"given":"Firas B.","family":"Badin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-9342","authenticated-orcid":false,"given":"Philip E.","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Shunyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaqil N.","family":"Kassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5675-8214","authenticated-orcid":false,"given":"Catherine","family":"Labb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral","family":"Rabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmood H.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Migas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Gowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-9767","authenticated-orcid":false,"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badri","family":"Rengarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Hanvesakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109644_b0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109644_b0010","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. PDQ small cell lung cancer treatment. National Cancer Institute. Updated May 14, 2025. https:\/\/www.cancer.gov\/types\/lung\/hp\/small-cell-lung-treatment-pdq (Accessed September 10, 2025)."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109644_b0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109644_b0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109644_b0025","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109644_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2019.02.026","article-title":"Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - results from the prospective German TLK cohort study","volume":"130","author":"Steffens","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109644_b0035","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109644_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1634\/theoncologist.9-2-173","article-title":"Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status","volume":"9","author":"Treat","year":"2004","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109644_b0045","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1111\/1759-7714.14712","article-title":"Prognostic factors for survival in extensive-stage small cell lung cancer: an Italian real-world retrospective analysis of 244 patients treated over the last decade","volume":"13","author":"Longo","year":"2022","journal-title":"Thorac. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109644_b0050","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/1759-7714.13846","article-title":"Prognostic factor analysis of patients with small cell lung cancer: real-world data from 988 patients","volume":"12","author":"Ma","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2026.109644_b0055","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/diagnostics14141572","article-title":"Topotecan in a real-world small-cell lung cancer cohort: prognostic biomarkers improve selection of patients for second-line treatment","volume":"14","author":"Lambrecht","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109644_b0060","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109644_b0065","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1997.15.5.2090","volume":"15","author":"Ardizzoni","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109644_b0070","unstructured":"Teva Pharmaceutical Industries Ltd. TOPOTECAN injection, for intravenous use. Updated December 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/200582s003lbl.pdf (Accessed June 29, 2025)."},{"key":"10.1016\/j.lungcan.2026.109644_b0075","unstructured":"Jazz Pharmaceuticals, Inc. ZEPZELCA\u00ae (lurbinectedin) for injection, for intravenous use. Updated February 2026. https:\/\/pp.jazzpharma.com\/pi\/zepzelca.en.USPI.pdf (Accessed March 17, 2026)."},{"key":"10.1016\/j.lungcan.2026.109644_b0080","unstructured":"Amgen, Inc. IMDELLTRA (tarlatamab-dlle) for injection, for intravenous use. Updated November 2025. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Imdelltra\/imdelltra_fpi.pdf (Accessed January 12, 2026)."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109644_b0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/molecules29020331","article-title":"Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment\u2014progresses in their use in combined cancer therapy","volume":"29","author":"Povo-Retana","year":"2024","journal-title":"Molecules"},{"issue":"10495","key":"10.1016\/j.lungcan.2026.109644_b0090","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109644_b0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109644_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109644_b0105","article-title":"Epidemiology of SCLC in the United States from 2000 to 2019: a study utilizing the Surveillance, Epidemiology, and End Results registry","volume":"6","author":"Wells","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109644_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115595","article-title":"Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: a multicentric international cohort","volume":"226","author":"Scattolin","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109644_b0115","doi-asserted-by":"crossref","unstructured":"A. Desai, C.J. Smith, Y. Ashara, et al, Real-world outcomes with lurbinectedin in second-line setting and beyond for extensive stage small cell lung cancer, Clin. Lung Cancer 24 (8) (2023) 689\u2013695 e1, https:\/\/doi.org\/10.1016\/j.cllc.2023.09.001.","DOI":"10.1016\/j.cllc.2023.09.001"},{"key":"10.1016\/j.lungcan.2026.109644_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108598","article-title":"Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes","volume":"205","author":"Krayim","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109644_b0125","first-page":"149","article-title":"Real-world outcomes with lurbinectedin in second line and beyond for extensive stage small cell lung cancer in Korea","volume":"15","author":"Shim","year":"2024","journal-title":"Lung Cancer (Auckl.)"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109644_b0130","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/14796694.2025.2499441","article-title":"Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer","volume":"21","author":"Ganti","year":"2025","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109644_b0135","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/imj.16348","article-title":"Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme","volume":"54","author":"Alexander","year":"2024","journal-title":"Intern. Med. J."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109644_b0140","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","article-title":"Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer","volume":"29","author":"Shaw","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109644_b0145","unstructured":"Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals provides update on Zepzelca\u00ae (lurbinectedin) phase 3 LAGOON trial in second-line small cell lung cancer. Updated June 12, 2026. https:\/\/investor.jazzpharma.com\/node\/22966\/pdf (Accessed July 17, 2026)."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109644_b0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109644_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211020529","article-title":"An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer","volume":"13","author":"Patel","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109644_b0160","article-title":"Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer","volume":"5","author":"Chakraborty","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"8 suppl 1","key":"10.1016\/j.lungcan.2026.109644_b0165","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1158\/1538-7445.AM2025-5837","article-title":"Abstract 5837: Lurbinectedin-induced transcriptional reprogramming: a pathway to sensitise SCLC to immunotherapy","volume":"85","author":"Russo-Cabrera","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109644_b0170","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: the phase I\/II LUPER study","volume":"20","author":"Calles","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.lungcan.2026.109644_b0175","first-page":"8013","article-title":"Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: results of the 2SMALL phase 1\/2 study (NCT04253145)","volume":"43","author":"Aix","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109644_b0180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cllc.2025.02.015","article-title":"Unmet needs in maintenance therapy for extensive stage small cell lung cancer","volume":"26","author":"Paz-Ares","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109644_b0185","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109644_b0190","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2026.109644_b0195","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109644_b0200","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0000000000000588","article-title":"Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy","volume":"10","author":"Evans","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109644_b0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109644_b0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:21Z","timestamp":1792718301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226007051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":42,"alternative-id":["S0169500226007051"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109644","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109644"}}